Earnings ·
Reports Q3 net revenue of $216.3M and announces $50M accelerated share repurchase
COLLCollegium Pharmaceutical, Inc
Collegium Pharmaceutical reported third-quarter 2026 financial results, generating record quarterly net revenues of $216.3 million, a 3% increase year-over-year. Adjusted EBITDA was $121.6 million, down 9% from the prior year period. The company announced a $50 million accelerated share repurchase program in Q3, with final settlement expected before year-end. JORNAY PM net revenue reached a record $51.9 million, up 24%, while AZSTARYS contributed $26.5 million in its first full quarter under Collegium ownership. The company reaffirmed its full-year 2026 guidance for product revenues of $825 to $855 million and adjusted EBITDA of $445 to $470 million. Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and pain conditions.